Medical Oncology Group of Australia / Roche Products Australia / Roche Products Pty Ltd / MSAC / /
Currency
USD / /
Event
Product Issues / FDA Phase / Product Recall / /
IndustryTerm
treatment of HER2 positive early breast cancer / health services / agreed clinical protocols / health technology assessments / breast cancer treatment / /
MedicalCondition
HER2 positive early breast cancer / HER2 positive breast cancer / III disease / HER2 positive metastatic breast cancer / locally advanced breast cancer / disease / early breast cancer / tumour / breast cancer / /
Pharmaceutical Benefits Advisory Committee / Therapeutic Goods Administration / Department of Health / Australian Health Ministers’ Advisory Council / Medicare / /
Position
Governor / Minister / Executive / consultant physician / /
Public Summary Document Application No. 1230 – HER2 ISH testing for access to trastuzumab for neoadjuvant breast cancer Applicant: Roche Products Pty Ltd Australia Date of MSAC consideration: 2 August 2012